Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602918" target="_blank" >RIV/61989592:15110/20:73602918 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/20:00116154 RIV/00216208:11110/20:10412539 RIV/00216208:11130/20:10412539 RIV/00216208:11140/20:10412539 a 5 dalších
Výsledek na webu
<a href="https://www.dovepress.com/regorafenib-for-metastatic-colorectal-cancer-an-analysis-of-a-registry-peer-reviewed-fulltext-article-CMAR" target="_blank" >https://www.dovepress.com/regorafenib-for-metastatic-colorectal-cancer-an-analysis-of-a-registry-peer-reviewed-fulltext-article-CMAR</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/CMAR.S255332" target="_blank" >10.2147/CMAR.S255332</a>

Jazyk výsledku
angličtina
Název v původním jazyce
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
Popis výsledku v původním jazyce
Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified.
Název v anglickém jazyce
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
Popis výsledku anglicky
Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified.

Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)